Journal of Clinical & Experimental Dermatology Research
Open Access

Rohith Kanchan

Publications

• Research Article
  To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital
  Author(s): Rohith Kanchan*, Sushruth Guruput Kamoji and Malteshgouda Ningappa Patil Rohith Kanchan*, Sushruth Guruput Kamoji and Malteshgouda Ningappa Patil
  
  Background: Pulsed corticosteroids are the mainstay in management of pemphigus but long term use is associated with numerous side effects. Biologics have shown promising results with minimal adverse effects but are expensive. Aim: To compare the cost of DCP & low-dose Rituximab therapy in pemphigus in a government tertiary hospital. Methods: We calculated the cost of DCP therapy (3 phases) and low dose Rituximab therapy in the treatment of pemphigus. These were considered under direct (medicines, usables for administering the medicines) and indirect costs (hospitalization, travel, loss of pay, the need for one attender) and a comparison were drawn. Results: The cost of DCP therapy for 3 phases over 27 months totalled up to 87,800 while the cost of Rituximab therapy over 1 month was 49,594. Low.. View More»
  DOI: 10.4172/2155-9554.1000387

  Abstract PDF

Relevant Topics